Ferroptosis Pathway In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Ferroptosis Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ferroptosis is an iron-dependent, lipid peroxidation-driven form of non-apoptotic cell death that has emerged as a critical mechanism in neurodegenerative diseases. Unlike apoptosis, ferroptosis is characterized by iron accumulation, lipid peroxidation, and glutathione depletion, leading to plasma membrane damage and cell death.
flowchart TD
A[Iron Overload] --> B[Iron Accumulation<br/>Ferrous Iron Fe2+] -->
B --> C[Lipid Peroxidation<br/>ROS Generation] -->
C --> D[GPX4 Inactivation] -->
D --> E[ lipid-ROS Accumulation] -->
E --> F[Membrane Damage] -->
F --> G[Cell Death] -->
H[Glutathione Depletion] --> D
H --> I[System Xc- Inhibition] -->
I --> J[Cystine Import Block] -->
J --> H
K[ACSLA4 Activation] --> C
K --> L[PUFA Peroxidation] -->
L --> C
M[FSP1 Loss] --> N[CoQ10 Depletion] -->
N --> O[ lipid-ROS Generation] -->
O --> C
P[Transsulfuration Pathway] --> Q[Homocysteine] -->
Q --> R[Glutathione Synthesis] -->
R --> H
| Component |
Role |
Relevance to Neurodegeneration |
| GPX4 |
Glutathione peroxidase 4, reduces lipid peroxides |
Key regulator; inhibited in AD, PD, ALS |
| System Xc- |
Cystine/glutamate antiporter (SLC7A11) |
Import of cystine for GSH synthesis |
| SLC7A11 |
Subunit of System Xc- |
Mutated in some cancers; target for therapy |
| ACSLA4 |
Acyl-CoA synthetase long-chain family 4 |
Catalyzes PUFA activation for peroxidation |
| FSP1 |
Ferroptosis suppressor protein 1 |
CoQ10-dependent antioxidant |
| NCOA4 |
Nuclear receptor coactivator 4 |
Regulates ferritinophagy, iron release |
| DMT1 |
Divalent metal transporter 1 |
Iron import into cells |
| Ferritin |
Iron storage protein (FTL, FTH) |
Iron homeostasis |
| SLC40A1 |
Ferroportin, iron exporter |
Iron efflux |
| TFR1 |
Transferrin receptor 1 |
Cellular iron uptake |
| Nrf2 |
Nuclear factor erythroid 2-related factor 2 |
Antioxidant response regulator |
- Iron accumulation: Elevated iron in AD brain (basal ganglia, cortex) correlating with disease severity
- Aβ interaction: Aβ can bind iron and promote ROS generation
- GPX4 dysregulation: Reduced GPX4 activity in AD hippocampus
- Ferritin elevation: Elevated ferritin in CSF as potential biomarker
- Lipid peroxidation: Increased 4-HNE and MDA in AD brain
- Therapeutic implications: Iron chelators (deferoxamine, deferasirox), GPX4 activators
- Iron accumulation: Elevated iron in substantia nigra pars compacta (SNpc) - characteristic finding
- Neuromelanin: Iron binding to neuromelanin may trigger ferroptosis
- GSH depletion: Severely reduced GSH in SNpc of PD patients
- System Xc- dysfunction: Imported cystine/glutamate antiporter reduced in PD
- DMT1 upregulation: Increased iron transporter in dopaminergic neurons
- Therapeutic implications: Iron chelation, glutathione augmentation, System Xc- activators
- GPX4 mutations: Rare GPX4 variants associated with ALS
- Lipid peroxidation: Elevated 4-HNE in ALS spinal cord
- Iron dysregulation: Increased iron in motor cortex and spinal cord
- System Xc- impairment: Cystine/glutamate transporter dysfunction
- Therapeutic implications: Ferrostatin-1 (experimental), iron chelators, lipid peroxidation inhibitors
- Iron accumulation: Elevated iron in striatum and cortex of HD patients
- GPX4 dysfunction: Impaired GPX4 activity with mutant huntingtin
- Glutathione depletion: Reduced GSH in HD brain
- Mitochondrial dysfunction: Contributes to iron-mediated ROS
- Therapeutic implications: Iron chelation, antioxidant therapy
| Feature |
Ferroptosis |
Apoptosis |
Necroptosis |
Pyroptosis |
| Morphology |
Small dense mitochondria |
Chromatin condensation |
Organelle swelling |
Cell swelling |
| Membrane |
Intact until late stage |
Blebbing |
Rupture |
Pore formation |
| Caspase involvement |
No |
Yes (caspase-3/8/9) |
No |
Yes (caspase-1/4/5) |
| DNA fragmentation |
No |
Yes |
No |
No |
| Energy requirement |
ATP-dependent |
ATP-dependent |
ATP-independent |
ATP-dependent |
| Key regulators |
GPX4, Iron |
Bcl-2, caspases |
RIPK1/3, MLKL |
NLRP3, gasdermin D |
- Ferrostatin-1: Lipophilic antioxidant (experimental)
- Liproxstatin-1: GPX4 stabilizer (experimental)
- Vitamin E: Chain-breaking antioxidant
- CoQ10: Membrane antioxidant
- Deferoxamine (DFO): FDA-approved iron chelator
- Deferasirox: Oral iron chelator
- Deferiprone: Iron chelator crossing BBB
- Clioquinol: Metal-protein attenuating compound
- N-acetylcysteine (NAC): GSH precursor
- Buthionine sulfoximine (BSO): Inhibits GSH depletion
- System Xc- activators: Promote cystine uptake
- Statins: May reduce lipid peroxidation
- Omega-3 fatty acids: Reduce PUFA peroxidation susceptibility
- FSP1 inhibitors: Target alternative ferroptosis pathway
- Nrf2 activators: Boost antioxidant response
- Ferritinophagy inhibitors: Reduce labile iron pool
| Biomarker |
Sample |
Changes in Neurodegeneration |
| Ferritin |
CSF, serum |
Elevated in AD, PD |
| Transferrin |
CSF, serum |
Altered in AD, PD |
| Iron |
Brain (MRI), CSF |
Elevated in PD, AD |
| 4-HNE |
Brain tissue, CSF |
Elevated in AD, PD, ALS |
| MDA |
Brain tissue, CSF |
Elevated in AD, PD, HD |
| 8-OHdG |
Urine, CSF |
Elevated in PD, AD |
| GPX4 activity |
Brain tissue |
Decreased in AD, PD |
| GSH |
Brain tissue, CSF |
Decreased in PD, HD |
- Mitochondrial ROS promotes lipid peroxidation
- Iron-sulfur cluster damage releases iron
- Mitochondrial dysfunction impairs GSH regeneration
- Microglial iron accumulation triggers inflammation
- NF-κB activation can promote ferroptosis
- Cyclooxygenase-2 (COX-2) links inflammation to ferroptosis
- Aβ and α-syn can bind iron
- Protein aggregates may impair iron homeostasis
- Ferritinophagy linked to protein clearance
- Iron accumulates with aging (brain iron theory of aging)
- GSH synthesis declines with age
- Nrf2 activity decreases with age
Ferroptosis Pathway In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Ferroptosis Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Dixon SJ et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-1072. PMID:22632970
- Stockwell BR et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171(2):273-285. PMID:28985560
- Weiland A et al. Ferroptosis and its role in neurodegenerative diseases. J Neurochem. 2019;149(4):487-505. PMID:30614876
- Maher P et al. The role of ferroptosis in the pathogenesis of Alzheimer's disease. Front Cell Neurosci. 2022;16:892519. PMID:35983276
- Sun Y et al. Ferroptosis in Parkinson's disease: molecular mechanisms and therapeutic potential. Front Cell Neurosci. 2021;15:728158. PMID:34776883
- Chen L et al. Ferroptosis: a novel therapeutic target for ALS. Front Cell Neurosci. 2021;15:694023. PMID:34512297
- Do Van B et al. Ferroptosis, a newly characterized form of cell death in Parkinson's disease. Mov Disord. 2016;31(1):85. PMID:26757192
- Zhang Y et al. Ferroptosis in Huntington's disease: a potential therapeutic target. Mol Neurobiol. 2022;59(7):4512-4525. PMID:35503176
- Conrad M et al. Synthesis of 4-hydroxynonenal (4-HNE) in neurological diseases. Free Radic Biol Med. 2021;175:82-93. PMID:34284070
- Nunez MT et al. Iron, copper and Alzheimer's disease. J Alzheimers Dis. 2020;75(s1):S85-S97. PMID:32176656
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%